The Acquisition of Drugs and Biologics for Chemical and Biological Warfare DefenseDepartment of Defense Interactions with the Food and Drug Administration (2003) By Richard A. Rettig, Jennifer Brower, Orlie Yaniv
 
The 1990-1991 Gulf War made clear the U.S. Department of Defense’s (DoD’s) need to effectively acquire drugs and biologics, mainly vaccines, as American troops faced the real threat of chemical and biological warfare (CBW) agents being used in combat. More than a decade after the war, DoD still experiences acute obstacles in obtaining CBW defense supplies — most recently magnified by the department’s attempt to acquire the anthrax vaccine for all its personnel. Key to this acquisition success for the department is its relationship with the U.S. Food and Drug Administration (FDA), which oversees compliance of all licensed drugs and the testing of new medications and vaccines. The DoD-FDA relationship specifically involves matters of licensing, the use of Investigational New Drugs in combat, and the compliance of drug and biologics producers with manufacturing requirements. How can effective communication and procedures improve between the two government entities? The authors recommend such changes as centralizing authority for DoD-FDA relations for CBW drugs and biologics in the Office of the Secretary of Defense and implementing training on FDA regulations for DoD acquisition personnel. Such progress is crucial as the U.S. military faces a variety of new threats in the post-9/11 world.
 
Soft Cover
77 Pages
In Good Condition